Search Results for “acquisition” – Page 5 – media

Bayer needs ‘midsize acquisition’ to reach $10B oncology sales goal, exec says

Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said.Right now, Bayer’s Nubeqa leads the charge in the company’s oncology department, with its sales projected to peak at more than 3 billion euros. In addition, the company’s acquisitions of Vividion Therapeutics, BlueRock Therapeutics and Noria Therapeutics in recent years have bolstered its research capabilities. “We’ve done a lot of activity to fill our early pipeline,” Roth said in an interview with Fierce Pharma on the sidelines of the American Society of Clinical Oncology’s 2023 annual meeting. “But if we want to achieve that top 10 spot in the next four to six years, it’s going to take the right midsize acquisition to get there.” Roth agreed ...
- Source: drugdu
- 116
- June 15, 2023
Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition

Dive Brief Boston Scientific has canceled a planned $230 million acquisition of a majority stake in M.I.Tech, a Korean manufacturer of non-vascular stents. The U.S. Federal Trade Commission (FTC) shared news of the cancelation, claiming that Boston Scientific took the action in response to investigations by its staff and overseas enforcement partners. Boston Scientific, which is reportedly considering a $10 billion takeover of cardiovascular device maker ShockWave, agreed to buy a 64% stake in M.I.Tech in June and originally expected to close the deal in the second half of 2022. Dive Insight M.I.Tech is a publicly traded Korean manufacturer of medical devices for endoscopic and urologic procedures, including a line of non-vascular, self-expanding metal stents that Boston Scientific has distributed in Japan since 2015. At the time of the agreement, Boston Scientific framed the products as complementary to its portfolio, and the deal as a way to help M.I.Tech expand ...
- Source: drugdu
- 86
- May 29, 2023
Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows

Pfizer plans to raise $31 billion through a debt offering to fund its proposed acquisition of cancer drug maker Seagen, for what would be its largest takeover since 2009, according to a new filing with the Securities and Exchange Commission. Pfizer expects to complete the $43 billion Seagen buyout later this year or in early 2024. The debt offering is expected to close Friday, according to a prospectus supplement New York-based Pfizer filed with the SEC late Tuesday. The pharma giant’s debt offering would be the biggest since CVS Health sold $40 billion of bonds in 2018 to finance its acquisition of health insurer Aetna. Pfizer’s move comes as other corporations including Apple, T-Mobile and Merck rush to tap the U.S. bond market ahead of a potential spike in borrowing costs sparked by the debt ceiling standoff. Pfizer’s stock price dropped slightly on Wednesday. The company said it will secure ...
- Source: drugdu
- 127
- May 19, 2023
Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition

Quest Diagnostics is boosting its capabilities in cancer, paying $300 million to acquire a Johns Hopkins University spinout whose technology identifies cancer cells in order to guide treatment decisions. The Secaucus, New Jersey-based diagnostics giant on Thursday announced the cash acquisition of Haystack Oncology. The Baltimore-based startup is part of a growing area in cancer testing called liquid biopsies, tests that detect cancer by finding circulating tumor DNA in a patient’s blood sample. Grail and Guardant Health are among the companies that market tests that detect early signs of cancer, enabling clinicians to intervene sooner. Haystack’s focus is minimal residual disease—detecting cancer cells that remain following initial treatment with surgery or a drug. Test results help clinicians assess how well the initial treatment worked and whether additional treatment, called an adjuvant, is necessary to kill any lingering cancer cells. That’s important because additional treatment, often a chemotherapy, introduces a wide ...
- Source: drugdu
- 175
- April 29, 2023
Fujifilm acquisition of Hitachi diagnostic imaging business delayed by COVID-19

Fujifilm Corporation’s planned $1.63 billion acquisition of Hitachi’s diagnostic imaging business has been put on hold in the midst of the ongoing COVID-19 pandemic. The Japanese healthcare giants, which began discussing the deal back in December, were aiming to complete the acquisition some time in July. Fujifilm, however, now says that “delays in some of the preparations” brought on by the spread of the virus have changed the completion schedule and that both parties will need more time to hammer out and finalize the details. “Due to the spread of CIVD19 globally, preparations for regulatory laws related to matters and clearance for anti-monopoly have been delayed. Government offices, legal offices and others impacted by lock downs and stay at home measures have slowed these activities,” Dave Wilson, director of communications for Hitachi Healthcare Americas, told HCB News. Fujifilm has delayed a planned acquisition of Hitachi’s diagnostic imaging-related business due to the ...
- Source: drugdu
- 309
- November 6, 2020
Covid-19
Nine digital health mergers and acquisitions from the first quarter of 2018

The first quarter of 2018 was light on mergers and acquisitions compared to previous quarters, but those that did crop up were significant, including major companies like Fitbit, Allscripts, Roche, and Johnson & Johnson.
- Source: MobiHealthNews
- 498
- April 2, 2018
digital health Market Views merger-and-acquisition
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy

Celgene Corporation (NASDAQ:CELG) today announced that it has completed the acquisition of Juno Therapeutics, Inc. As a result, the common stock of Juno will no longer be listed for trading on the NASDAQ Global Select Market.
- Source: ir.celgene
- 589
- March 8, 2018
cellular immunotherapy Market Views
As the industry is going down, more and more pharmaceutical companies are seeking to “exit”?

In February this year, China Resources Double Crane acquired 100% of the equity of China Resources Zizhu for 3.1 billion yuan, enriched Double Crane’s specialty product line through Zizhu’s core products such as Yuting and Jin Yuting, formed a “women’s health + pediatrics” specialty product sequence, and improved the product matrix; in March, Xintian Pharmaceutical, which mainly engages in traditional Chinese medicine business, announced that it plans to acquire 85.12% of Huilun Pharmaceutical’s equity through issuing shares, expanding its business to the field of small molecule chemical drugs; in June, the domestic contrast agent leader Beilu Pharmaceutical acquired Chengde Tianyuan Pharmaceutical for 202 million yuan. 80% equity, expanding its coverage in the field of traditional Chinese medicine; in October, the plan for SinoVac (Shijiazhuang Pharmaceutical Innovation) to acquire Shijiazhuang Baike was released. SinoVac will acquire 100% equity of Shijiazhuang Baike for a total price of up to 7.6 billion yuan ...
- Source: drugdu
- 23
- November 22, 2024
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 23
- November 22, 2024
AstraZeneca’s new dual anti-cancer drug approved for clinical trials in China

On November 15, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that AstraZeneca’s Class 1 new drug AZD0486 was approved for two clinical trials with implicit approval, which are intended to be used for the treatment of previously untreated follicular lymphoma in adults; and relapsed and refractory follicular lymphoma in adults who have received at least 2 lines of systemic treatment or more. Public information shows that AZD0486 is a CD19/CD3-targeted bispecific T cell adaptor protein under development by AstraZeneca, which is a next-generation T cell adaptor. This is the first time that a drug has been approved for clinical trials in China for the indication of follicular lymphoma (FL). In a clinical study recently published by AstraZeneca, the product showed an overall response rate (ORR) of up to 96% when used to treat patients with relapsed/refractory FL (R/R FL). ...
- Source: drugdu
- 31
- November 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.